| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| February 5, 2026 | ±3.0% | +9.8% | under-priced |
| October 30, 2025 | ±1.7% | +15.4% | under-priced |
| May 1, 2025 | ±2.0% | +3.0% | under-priced |
| January 30, 2025 | ±1.7% | +0.4% | over-priced |
| November 1, 2024 | ±1.8% | +7.0% | under-priced |
| May 2, 2024 | ±1.4% | +0.8% | over-priced |
| February 1, 2024 | ±2.0% | -3.8% | under-priced |
| November 3, 2023 | ±2.1% | +6.9% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | — | $65.6B | $471M |
| Q1 FY2026 | $1.88 | $64.0B | $454M |
| Q4 FY2025 | — | $60.2B | $243M |
| Q3 FY2025 | — | $54.9B | $508M |
Cardinal Health, Inc. (CAH) reports in 52 days, with the next report estimated for August 4, 2026. Across the last 8 reports, options priced an average ±2.0% earnings move while the stock actually moved 5.9% on average — the market has tended to under-price CAH's earnings risk. Fundamentals into the print: EPS up 0.0% year-over-year, revenue up 18.8%. QuantLogix's live 5-factor engine currently reads CAH as a buy at 65/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →